1883747-71-4

Quabodepistat (OPC-167832) (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic??characteristic. The plasma reaches peak at 0.5 h to 1.0 h (t_max) and is eliminated with a half-life (t_1/2) of 1.3 h to 2.1 h?Quabodepistat distribution in the lungs is approximately 2 times higher than that in plasma, and the?C_max?and AUC_t of Quabodepistat in plasma and the lungs shows dose dependency^[1].Quabodepistat (oral administration; 0.625-10 mg/kg; 4?weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625?mg/kg to 2.5?mg/kg. In a?M. tuberculosis?Kurono-infected ICR female mice model. Quabodepistat combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone^[1].^[1].Quabodepistat (oral gavage; 2.5?mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate^[1].